FibroGen Inc reports results for the quarter ended in March - Earnings Summary

Kyntra Bio

06/05/2024 22:51

* FibroGen Inc  FGEN.OQ  reported a quarterly adjusted loss
of 33
cents​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -81
cents.  The mean expectation of two analysts for the quarter was
for a loss of 42 cents per share. Wall Street expected
results to range from -53 cents to -31 cents per share.
    * Revenue rose 54.6% to $55.90 million from a year ago;
analysts
expected $36.67 million. 
    * FibroGen Inc shares had fallen by 51.5% this quarter and
gained 28.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 5% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "sell"

Wall Street's median 12-month price target for FibroGen Inc is
$1.75 
This summary was machine generated from LSEG data May 6 at 09:51
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.42          -0.33          Beat
 Dec. 31 2023      -0.42          -0.57          Missed
 Sep. 30 2023      -0.68          -0.52          Beat
 Jun. 30 2023      -0.70          -0.90          Missed